Diagnostic Strategies for Prostate Cancer

Eyre, 2004, Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association, Circulation, 109, 3244, 10.1161/01.CIR.0000133321.00456.00 Bartsch, 2001, Prostate cancer mortality after introduction of prostate specific antigen mass screening in the federal state of Tyrol, Austria, Urology, 58, 417, 10.1016/S0090-4295(01)01264-X Schröder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696 Anast, 2004, Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screened population?, Urology, 64, 544, 10.1016/j.urology.2004.04.008 Gilliland, 1996, Improving survival for patients with prostate cancer diagnosed in the prostate specific antigen era, Urology, 48, 67, 10.1016/S0090-4295(96)00083-0 Paquette, 2001, Improvements in pathologic staging for African American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma, Cancer, 92, 2673, 10.1002/1097-0142(20011115)92:10<2673::AID-CNCR1621>3.0.CO;2-2 Canfield, 2009, Annual screening for prostate cancer did not reduce mortality from prostate cancer, Evid Based Med, 14, 104, 10.1136/ebm.14.4.104 Catalona, 1993, Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening, JAMA, 270, 948, 10.1001/jama.270.8.948 Sun, 2001, Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database and analysis in the PSA era, Urol Oncol, 203, 10.1016/S1078-1439(01)00145-4 Stephenson, 1997, Population-based prostate cancer trends in the United States: patterns of change in the era of prostate specific antigen, World J Urol, 15, 331, 10.1007/BF01300179 Roehl, 2004, Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results, J Urol, 172, 910, 10.1097/01.ju.0000134888.22332.bb Catalona, 1997, Prostate cancer detection in men with serum PSA concentrations of 2.6 ng/ml to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements, JAMA, 277, 1452, 10.1001/jama.277.18.1452 Horninger, 2002, Complexed prostate specific antigen for early detection of prostate cancer in men with serum prostate specific antigen levels of 2 to 4 nanograms per millilitre, Urology, 60, 31, 10.1016/S0090-4295(02)01693-X Oesterling, 1993, Serum prostate-specific antigen in a community-based population of healthy men: established age-specific reference ranges, JAMA, 270, 860, 10.1001/jama.270.7.860 Morgan, 1996, Age-specific reference ranges for prostate-specific antigen in black men, N Engl J Med, 335, 304, 10.1056/NEJM199608013350502 Labrie, 1999, Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial, Prostate, 38, 83, 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B Newschaffer, 2009, Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort, J Natl Cancer Inst, 92, 613, 10.1093/jnci/92.8.613 Carroll P, Prostate-Specific Antigen Best Practice Statement: 2009 Update (American Urological Association Education and Research, Inc, 2009), http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf, accessed April 2011. Brawer, 2000, Complexed prostate-specific antigen provides significant enhancement of specificity compared with total prostate-specific antigen for detecting prostate cancer, J Urol, 163, 1476, 10.1016/S0022-5347(05)67646-X Yokomizo, 2009, Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy, Urol Int, 82, 280, 10.1159/000209358 Djavan, 1999, PSA, PSA density, PSA density of transitional zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml, Urology, 54, 517, 10.1016/S0090-4295(99)00153-3 Catalona, 2006, Viewpoint: expanding prostate cancer screening, Ann Intern Med, 144, 441, 10.7326/0003-4819-144-6-200603210-00012 Catalona, 1998, Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA, 279, 1542, 10.1001/jama.279.19.1542 Djavan, 1998, Prostate-specific antigen density of the transitional zone for early detection of prostate cancer, J Urol, 160, 411, 10.1016/S0022-5347(01)62911-2 Djavan, 2000, Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 patients, J Urol, 163, 1144, 10.1016/S0022-5347(05)67711-7 Catalona, 1999, Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model, Urology, 54, 220, 10.1016/S0090-4295(99)00185-5 Piironen, 1996, In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples, Urology, 48, 81, 10.1016/S0090-4295(96)00616-4 Ahyai, 2010, The presence of prostate cancer on saturation biopsy can be accurately predicted, BJU Int, 105, 636, 10.1111/j.1464-410X.2009.08744.x Benson, 1992, The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen, J Urol, 147, 817, 10.1016/S0022-5347(17)37394-9 Kuriyama, 1999, Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels, Jpn J Clin Oncol, 29, 617, 10.1093/jjco/29.12.617 Borer, 1998, Age specific prostate specific antigen reference ranges: population specific, J Urol, 159, 444, 10.1016/S0022-5347(01)63945-4 Ferreira, 2005, Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer, Int Braz J Urol, 31, 137, 10.1590/S1677-55382005000200008 Carter, 1992, Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease, Cancer Res, 52, 3323 Ornstein, 1997, Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers, J Urol, 157, 2179, 10.1016/S0022-5347(01)64708-6 Porter, 1994, The significance of short term PSA change in men undergoing ultrasound guided prostate biopsy, J Urol, 264, 9 Nixon, 1998, Comparison of three investigational assays for the free form of prostate specific antigen, J Urol, 160, 420, 10.1016/S0022-5347(01)62913-6 Mikolajczyk, 2000, A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue, Cancer Res, 60, 756 Jansen, 2010, Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection, Eur Urol, 57, 921, 10.1016/j.eururo.2010.02.003 Figueroa, 1998, Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer, J Urol, 159, 1379, 10.1016/S0022-5347(01)63620-6 Stattin, 2000, Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study, J Natl Cancer Inst, 92, 1910, 10.1093/jnci/92.23.1910 Thomas, 2010, Effect of intermittent fasting on prostate cancer tumor growth in a mouse model, Prostate Cancer Prostatic Dis, 13, 350, 10.1038/pcan.2010.24 Schedlich, 1987, Primary structure of a human glandular kallikrein gene, DNA, 6, 429, 10.1089/dna.1987.6.429 Darson, 1999, Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases, Urology, 53, 939, 10.1016/S0090-4295(98)00637-2 Partin, 1999, Use of human glandular kallikrein 2 for detection of prostate cancer: preliminary analysis, Urology, 54, 839, 10.1016/S0090-4295(99)00270-8 Becker, 2000, Clinical value of human glandular kallikrein 2 and free and total prostate specific antigen in serum form a population of men with prostate specific antigen levels 3 ng/ml or greater, Urology, 55, 694, 10.1016/S0090-4295(99)00585-3 Benchikh, 2010, A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France, BMC Cancer, 10, 635, 10.1186/1471-2407-10-635 Nurmikko, 2001, Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate specific antigen lacking an internal cleavage site at Lys145-Lys146, Clin Chem, 47, 1415, 10.1093/clinchem/47.8.1415 Steuber, 2002, Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen, J Urol, 168, 1917, 10.1016/S0022-5347(05)64263-2 Linton, 2003, Benign prostate specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem, 49, 253, 10.1373/49.2.253 Denham, 2009, Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer, 115, 4477 Mikolajczyk, 2000, Seminal plasma contains “BPSA”, a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia, Prostate, 45, 271, 10.1002/1097-0045(20001101)45:3<271::AID-PROS11>3.0.CO;2-T Klausner, 2010, Long term prostate-specific antigen trends following subcapsular prostatectomy, Can J Urol, 17, 5442 Mikolajczyk, 2001, A truncated precursor form of prostate specific antigen is a more specific serum marker of prostate cancer, Cancer Res, 61, 6958 Mikolaiczyk, 2003, Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer, Keio J Med, 52, 86, 10.2302/kjm.52.86 Catalona, 2003, Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2.4-4 ng/ml, J Urol, 170, 2181, 10.1097/01.ju.0000095460.12999.43 Tosoian, 2010, PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer, ScientificWorld Journal, 10, 1919, 10.1100/tsw.2010.182 Herwig, 2005, Ability of PSA-positive circulating macrophages to detect prostate cancer, Prostate, 62, 290, 10.1002/pros.20141 Herwig, 2008, Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA, Eur J Clin Invest, 38, 430, 10.1111/j.1365-2362.2008.01953.x Jaraj, 2011, GAD1 is a biomarker for benign and malignant prostatic tissue, Scand J Urol Nephrol, 45, 39, 10.3109/00365599.2010.521189 Häggarth, 2011, Diagnostic biomarkers of prostate cancer, Scand J Urol Nephrol, 45, 60, 10.3109/00365599.2010.526141 Harden, 2003, Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostatic adenocarcinoma, J Urol, 169, 1138, 10.1097/01.ju.0000049627.90307.4d Steiner, 2010, Gene promoter methylation and its potential relevance in early prostate cancer diagnosis, Pathobiology, 77, 260, 10.1159/000318017 Muller, 2003, Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples, Urologe A, 42, 660 Bantis, 2009, Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas, Tumori, 95, 744, 10.1177/030089160909500618 Verhaegh, 2000, Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene, J Biol Chem, 275, 37496, 10.1074/jbc.M006293200 Liang, 1992, Differential display of eukaryotic messenger RNA by means of polymerase chain reaction, Science, 257, 967, 10.1126/science.1354393 Makarov, 2009, Biomarkers for prostate cancer, Ann Rev Med, 60, 139, 10.1146/annurev.med.60.042307.110714 Kollermann, 2006, Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer, BMC Urol, 6 Ploussard, 2010, Urine biomarkers in prostate cancer, Nat Rev Urol, 7, 101, 10.1038/nrurol.2009.261 Klecka, 2010, Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis, Anticancer Res, 30, 665 Floriano-Sánchez, 2009, DD3(PCA3) gene expression in cancer and prostatic hyperplasia, Clin Invest Med, 32, E258, 10.25011/cim.v32i6.10661 Ruiz-Aragón, 2010, Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis, Actas Urol Esp, 34, 346, 10.1016/j.acuro.2010.02.019 Jeronimo, 2001, Mitochondrial mutations in early stage prostate cancer and bodily fluids, Oncogene, 20, 5195, 10.1038/sj.onc.1204646 Richardson, 2009, Tissue-based quantification of 8-hydroxy-2’-deoxyguanosine in human prostate biopsies using quantitative fluorescence imaging analysis, Urology, 74, 1174, 10.1016/j.urology.2009.01.052 Wang, 2004, The expression and significance of survivin mRNA in urinary bladder carcinomas, J Cancer Res Clin Oncol, 130, 487, 10.1007/s00432-004-0561-z Fisker, 2007, Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy, Nucleosides Nucleotides Nucleic Acids, 26, 1427, 10.1080/15257770701542132 Dudderidge, 2010, Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments, Br J Cancer, 103, 701, 10.1038/sj.bjc.6605785 Tanaka, 2003, Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers, Med Sci Monit, 9, MT61 Lombardo, 1997, Preliminary evaluation of 5α-reductase type 2 in urine as potential marker for prostate disease, Steroids, 62, 682, 10.1016/S0039-128X(97)00066-4 Prior, 2010, Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer, World J Urol, 28, 681, 10.1007/s00345-010-0583-x Thompson, 2006, Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 98, 529, 10.1093/jnci/djj131 Ngo, 2011, The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients, J Urol, 185, 483, 10.1016/j.juro.2010.09.101 Nguyen, 2010, Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy, J Urol, 183, 529, 10.1016/j.juro.2009.10.007 Roobol, 2010, A risk-based strategy improves prostate-specific antigen–driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 Steyerberg, 2007, Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, J Urol, 177, 107, 10.1016/j.juro.2006.08.068 Kranse, 2008, A graphical device to represent the outcomes of a logistic regression analysis, an illustration of its possible use in prostate cancer screening and prostate cancer treatment counseling, Prostate, 68, 1674, 10.1002/pros.20840 Djavan, 2002, Novel artificial neural network for early detection of prostate cancer, J Clin Oncol, 20, 921, 10.1200/JCO.20.4.921 Stephan, 2007, Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men, World J Urol, 25, 95, 10.1007/s00345-006-0132-9 Smith, 2001, American Cancer Society guidelines for early detection of cancer: update of early detection guidelines for prostate, colorectal and endometrial cancers, CA Cancer J Clin, 51, 38, 10.3322/canjclin.51.1.38